Adaptimmune shares drop as Genentech terminates potential $3B deal
Adaptimmune and Genentech reached the research and licensing agreement in 2021.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ryan Sharrow Source Type: news
More News: Health Management | Pharmaceuticals